Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

NCT07246096 is registered in ClinicalTrials.gov with Changhai Hospital as lead sponsor.

NCT NCT07246096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07246096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
Lead sponsor
Changhai Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
February 20, 2026
Completion date
July 20, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune diseases, primary sjögren syndrome, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis